The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model

BACKGROUND: Tyrosine kinase inhibitor gefitinib is effective against lung cancer cells carrying mutant epidermal growth factor receptor (EGFR); however, it is not effective against lung cancer carrying normal EGFR. The breaking of immune tolerance against self epidermal growth factor receptor with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Ming-Derg, Yen, Meng-Chi, Lin, Chiu-Mei, Tu, Cheng-Fen, Wang, Chun-Chin, Lin, Pei-Shan, Yang, Huei-Jiun, Lin, Chi-Chen
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645394/
https://www.ncbi.nlm.nih.gov/pubmed/19178753
http://dx.doi.org/10.1186/1479-0556-7-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645394/
https://www.ncbi.nlm.nih.gov/pubmed/19178753
http://dx.doi.org/10.1186/1479-0556-7-2

Ejemplares similares